This piece treats the US side. The Chinese side is treated in the companion note, The Chinese gate. A contractual entitlement leaves. The operating capability does not. A fund organised outside the United States pays a US biotech for a percentage of net sales on a marketed product. It takes

Innoviva is a listed permanent-capital vehicle built on two GSK respiratory royalties. It files as a biopharmaceutical company. It behaves like a fund with an annuity attached, and it is in this series for that reason. A royalty stream it did not buy throws off around $240M a year

The US regime asks where the asset is. The Chinese regime asks who is holding it. For a royalty on ex-China sales, that difference decides whether the stream can be sold at all, and it produces a result the opposite of the one most deal teams assume.

A listed royalty company whose lead royalty is pledged in full, whose second royalty pays its milestones to somebody else, and whose licensee it is suing for the drug back.

Bridge financing is the shortest paper in the capital structure, and it is regularly written against some of the longest assets in it. The take-out provision is the machinery that governs how, when, and at whose cost the short paper is replaced. This is an account of both, worked

A royalty book carries a modified duration near five years, a discount rate in which the risk-free is now more than a third of the total, and a preferred return hurdle struck when the five-year point was under 1%. The asset has not changed. What an allocator gives

A pharmaceutical merger agreement fixes the price on the signing date and delivers it on the closing date. Between the two sit the tender offer clock, the shareholder vote, and the merger control timetable, and the interval runs from weeks to more than a year. Two financing problems live in

Two aggregators printed on consecutive days, in opposite structures. Royalty Pharma bought Zealand's remaining rusfertide economics outright for $100M, half on closing and half a year later, leaving the seller 0.25% of net sales above $1.5B. HealthCare Royalty took OPKO's mazdutide royalty as security

A royalty is only worth what someone will pay for it, and not everyone who writes those cheques is buying the same thing. The phrase "royalty fund" hides at least five different businesses. One buys finished, marketed royalties and clips the coupon. One funds the last year of